Literature DB >> 24790396

Alogliptin (nesina) for adults with type-2 diabetes.

Laura Dineen, Connie Law, Rebecca Scher, Eunice Pyon.   

Abstract

Alogliptin (Nesina) for adults with type-2 diabetes.

Entities:  

Year:  2014        PMID： 24790396      PMCID： PMC4005122     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  27 in total

1.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

2.  EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.

Authors:  William B White; George L Bakris; Richard M Bergenstal; Christopher P Cannon; William C Cushman; Penny Fleck; Simon Heller; Cyrus Mehta; Steven E Nissen; Alfonso Perez; Craig Wilson; Faiez Zannad
Journal:  Am Heart J       Date:  2011-09-14       Impact factor: 4.749

3.  Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.

Authors:  M Monami; I Dicembrini; E Mannucci
Journal:  Diabetes Obes Metab       Date:  2013-07-28       Impact factor: 6.577

Review 4.  Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

Authors:  Larry K Golightly; Caitlin C Drayna; Michael T McDermott
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

5.  Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.

Authors:  J Rosenstock; C Wilson; P Fleck
Journal:  Diabetes Obes Metab       Date:  2013-04-18       Impact factor: 6.577

6.  Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

Authors:  Paul Covington; Ronald Christopher; Michael Davenport; Penny Fleck; Qais A Mekki; Elisabeth R Wann; Aziz Karim
Journal:  Clin Ther       Date:  2008-03       Impact factor: 3.393

7.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.

Authors:  R E Pratley; M S Kipnes; P R Fleck; C Wilson; Q Mekki
Journal:  Diabetes Obes Metab       Date:  2009-02       Impact factor: 6.577

8.  Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.

Authors:  A Karim; P Covington; R Christopher; M Davenport; P Fleck; X Li; E Wann; Q Mekki
Journal:  Int J Clin Pharmacol Ther       Date:  2010-01       Impact factor: 1.366

9.  Alogliptin: a new addition to the class of DPP-4 inhibitors.

Authors:  Radha Andukuri; Andjela Drincic; Marc Rendell
Journal:  Diabetes Metab Syndr Obes       Date:  2009-07-21       Impact factor: 3.168

Review 10.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112
View more
  4 in total

Review 1.  The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.

Authors:  Melanie Davies; Sudesna Chatterjee; Kamlesh Khunti
Journal:  Clin Pharmacol       Date:  2016-06-23

Review 2.  The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect.

Authors:  Konstantinos Makrilakis
Journal:  Int J Environ Res Public Health       Date:  2019-07-30       Impact factor: 3.390

Review 3.  The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.

Authors:  Mohammed Altigani Abdalla; Harshal Deshmukh; Stephen Atkin; Thozhukat Sathyapalan
Journal:  Ther Adv Endocrinol Metab       Date:  2021-01-27       Impact factor: 3.565

4.  Alogliptin-Induced Minimal Change Nephrotic Syndrome and Interstitial Nephritis.

Authors:  Hisato Shima; Takuya Okamoto; Manabu Tashiro; Tomoko Inoue; Chiaki Masaki; Hiroaki Tada; Norimichi Takamatsu; Kazuhiko Kawahara; Kazuyoshi Okada; Toshio Doi; Jun Minakuchi; Shu Kawashima
Journal:  Kidney Med       Date:  2019-03-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.